查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1965889

奥美拉唑市场－全球产业规模、份额、趋势、机会和预测：按最终用途、销售管道、地区和竞争格局划分，2021-2031年

Omeprazole Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By End-Use Application, By Sales Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球奥美拉唑市场预计将从 2025 年的 22,670 吨成长到 2031 年的 31,470 吨，复合年增长率为 5.62%。

奥美拉唑是一种领先的质子帮浦阻断剂，广泛用于抑制胃酸分泌，治疗胃食道逆流、消化性溃疡和柔林格症候群等疾病。市场扩张的主要驱动力是全球慢性胃肠道疾病的日益增多，而这些疾病与老化、不良饮食和肥胖等生活方式因素密切相关。高处方率清楚地表明了这种持续的临床需求。例如，根据英国国家医疗服务体系（NHS）商业服务部门的数据，奥美拉唑将成为2025年英格兰处方量最大的药物之一，该财政年度的处方量约为3,600万剂。

市场概览
预测期 2027-2031
市场规模：2025年 22,670吨
市场规模：2031年 31470吨
复合年增长率：2026-2031年 5.62%
成长最快的细分市场 胃食道逆流症
最大的市场 北美洲

儘管市场消费量很高，但成长仍面临一个重大障碍：长期抑酸疗法的安全性日益受到关注。越来越多的临床证据表明，长期使用抑酸药物与骨折、微量营养素缺乏和肾臟疾病等不良后果有关，这迫使医疗专业人员采取更严格的减药策略。除了这些安全隐患外，来自低成本学名药的激烈竞争也给该领域的生产商带来了巨大的产生收入压力。

市场驱动因素

市场成长的主要驱动力是全球胃食道逆流症 (GERD) 和消化性溃疡盛行率的上升，而这一趋势主要受生活方式改变的影响。随着都市化进程的推进，人们的生活方式日益久坐，加工食品的消费量也随之增加。因此，与肥胖相关的胃肠道疾病激增，这种关联进一步推高了对抑酸药物的临床需求。该患者群体规模庞大，根据美国国立卫生研究院 (NIH) 估计，到 2024 年，全球 GERD 盛行率将达到约 13.98%。此外，代谢健康因素也直接加剧了这项需求。 2024 年 1 月在 ResearchGate 上发表的一项研究题为“肥胖与胃食道逆流的高发病率有关”，发现肥胖人群的 GERD 患病率为 30%，而非肥胖人群的患病率为 24%，这凸显了因体重相关问题而需要进行治疗性介入的必要性。

同时，价格亲民的非专利质子帮浦阻断剂的广泛市场渗透显着维持了其收入基础。专利到期后，低价非专利奥美拉唑的涌现扩大了患者的用药范围，使其成为处方药和非处方药市场的主力药。这种实惠的价格确保了患者不会因费用问题而放弃用药，从而维持了较高的处方量。奥美拉唑的使用量依然庞大；根据ClinCalc的「奥美拉唑－药物使用统计」资料库，截至2025年8月，奥美拉唑是美国处方量排名第十的药物，处方笺超过4,500万张。如此高的使用率巩固了其作为标准治疗药物的根深蒂固的地位，同时也确保了其在价格下行压力下仍能保持稳定的市场表现。

市场挑战

阻碍全球奥美拉唑市场扩张的关键挑战之一是对长期抑酸治疗的安全性监测日益加强。临床数据显示，长期使用质子帮浦阻断剂与骨折、微量营养素缺乏和慢性肾臟病等严重不利事件有关，因此医疗机构正积极采用更严格的减重药通讯协定。这种临床实践的转变强调最大限制地减少不必要的药物使用，并直接限制了以往支撑市场收入的重复处方量。系统性地重新评估长期治疗方案将导致处方频率降低，进而抑制市场成长。

为了佐证下降趋势，近期数据凸显了长期不当用药的普遍性。英国英国全科医学会2025年的评估发现，约62%接受质子帮浦阻断剂长期治疗的患者并无任何长期用药的医学指征。如此高的不当用药率迫使医疗委员会和保险公司实施严格的停药政策。因此，随着医疗系统根据安全指南调整处方行为，製造商面临销售大幅下降的局面，这直接降低了该行业的预期成长。

市场趋势

由于以患者为中心的液体製剂的研发，全球奥美拉唑市场正经历重大变革。这些液体製剂旨在满足吞嚥困难的儿童和老年患者的关键需求。与传统的固态剂型不同，这些创新的液体製剂能够为无法吞嚥胶囊或片剂的患者提供精准的剂量，提高患者的用药依从性，并在行业内开闢一个专业化的高价值细分市场。这一趋势的特点是增加对生产能力的投资，以支持确保药物稳定性的复杂给药系统。例如，在2024年12月发布的「Alkaloids AD Scopie 2025产业计画概要」中，该公司预计研发支出将成长10%，以更新产品系列併推动取得专利的高价值药物的商业化。这其中就包括新推出的即用型液体奥美拉唑。

同时，新型联合治疗的研发正日益受到关注，被视为应对幽门螺旋桿菌感染疾病治疗中日益严重的抗生素抗药性的有效手段。製药商正在开发将奥美拉唑与先进抗生素结合的固定剂量组合药物，以提高根除率和临床疗效。这种疗法超越了单纯抑制胃酸分泌的范畴，透过提供全面的治疗方法，帮助患者提高用药依从性，从而在竞争激烈的市场中脱颖而出。这些标靶治疗的商业性可行性已透过财务表现得到证实。根据RedHill Biopharma于2025年9月发布的《2025财年上半年财务业绩报告》，奥美拉唑复方製剂「Talicia」在2025财年上半年的净销售额达到380万美元，显示这些特製製剂正在获得市场认可。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球奥美拉唑市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 最终用途分类（十二指肠溃疡、胃溃疡、胃食道逆流、糜烂性食道炎、其他）
    • 销售管道（直销、间接销售）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美奥美拉唑市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲奥美拉唑市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区奥美拉唑市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：奥美拉唑在中东和非洲的市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：奥美拉唑在南美洲的市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球奥美拉唑市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Dr. Reddy's Laboratories Inc
  • Sandoz AG
  • Perrigo Company Plc.
  • Astrazeneca Plc
  • Amneal Pharmaceuticals, Inc
  • Mylan NV
  • Apotex, Inc.
  • Watson Co., Ltd..
  • Santarus Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 27399

The Global Omeprazole Market is projected to expand from 22.67 Thousand Tonnes in 2025 to 31.47 Thousand Tonnes by 2031, reflecting a compound annual growth rate of 5.62%. As a prominent proton pump inhibitor, omeprazole is extensively used to inhibit gastric acid secretion for treating ailments like gastroesophageal reflux disease, peptic ulcers, and Zollinger-Ellison syndrome. Market expansion is chiefly fueled by the increasing prevalence of chronic gastrointestinal conditions worldwide, a trend closely linked to aging demographics and lifestyle choices such as poor diet and obesity. High prescription rates illustrate this sustained clinical need; for example, data from the NHS Business Services Authority indicates that omeprazole was one of England's most dispensed drugs in 2025, with roughly 36 million items distributed during the fiscal year.

Market Overview
Forecast Period2027-2031
Market Size 202522.67 Thousand Tonnes
Market Size 203131.47 Thousand Tonnes
CAGR 2026-20315.62%
Fastest Growing SegmentGastroesophageal Reflux Disease
Largest MarketNorth America

Despite strong consumption levels, market growth faces a notable obstacle in the form of heightened scrutiny regarding the safety of long-term acid suppression therapy. Rising clinical concerns connecting prolonged use with adverse outcomes-such as bone fractures, micronutrient deficiencies, and kidney disease-have compelled healthcare practitioners to adopt more rigorous deprescribing strategies. These safety issues, coupled with fierce competition from low-cost generic substitutes, generate significant pressure on revenue generation for manufacturers operating in this sector.

Market Driver

The primary engine of market growth is the rising global incidence of Gastroesophageal Reflux Disease (GERD) and peptic ulcers, a trend largely shaped by evolving lifestyles. As urbanization accelerates, populations are increasingly adopting sedentary habits and consuming processed foods, resulting in a spike in obesity-associated gastrointestinal conditions. This relationship reinforces the clinical demand for acid suppressants. The scale of this patient population is immense; the National Institutes of Health estimated the global pooled prevalence of GERD at roughly 13.98% in 2024. Moreover, metabolic health factors directly intensify this requirement; a study published on ResearchGate in January 2024, titled 'Obesity is associated with higher prevalence of gastroesophageal reflux disease,' found that obese patients had a 30% GERD prevalence compared to 24% in non-obese individuals, highlighting how weight-related issues necessitate therapeutic intervention.

Simultaneously, the extensive market reach of affordable generic proton pump inhibitors has been fundamental in maintaining revenue streams. Since patent expirations, the availability of low-cost generic omeprazole has broadened access, establishing the drug as a staple in both prescription and over-the-counter markets. This affordability ensures that cost does not impede patient adherence, thereby keeping dispensation rates high. Usage volumes remain substantial; according to the 'Omeprazole - Drug Usage Statistics' database by ClinCalc in August 2025, omeprazole was the tenth most prescribed medication in the United States, with more than 45 million prescriptions written. This frequency confirms the drug's deep-rooted status as a standard of care, securing stable market performance despite downward pricing pressures.

Market Challenge

A pivotal challenge inhibiting the expansion of the Global Omeprazole Market is the intensified scrutiny surrounding the long-term safety of extended acid suppression therapy. As clinical data increasingly associates prolonged proton pump inhibitor use with serious adverse effects like bone fractures, micronutrient deficiencies, and chronic kidney disease, healthcare providers are actively adopting stricter deprescribing protocols. This modification in clinical practice emphasizes minimizing unnecessary medication usage, which directly restricts the volume of repeat prescriptions that have historically underpinned market revenue. The systematic move to re-evaluate long-term therapies necessitates a reduction in dispensing frequency, thereby curbing market growth.

Recent data highlighting the widespread nature of unjustified prolonged usage reinforces this contraction. An evaluation by the Royal College of General Practitioners in 2025 revealed that approximately 62% of patients receiving continuous proton pump inhibitor treatment lacked a recorded medical indication for such extended therapy. This significant rate of inappropriate use compels medical boards and insurers to implement rigorous discontinuation policies. Consequently, manufacturers are encountering a tangible reduction in consumption rates as healthcare systems adjust prescription behaviors to align with safety guidelines, directly diminishing the sector's projected growth.

Market Trends

The Global Omeprazole Market is being significantly transformed by the development of patient-centric liquid formulations designed to meet the critical needs of pediatric and geriatric patients with dysphagia. Unlike conventional solid dosages, these innovative liquid solutions facilitate accurate dosing and enhance adherence for individuals unable to swallow capsules or tablets, establishing a specialized, high-value niche within the industry. This trend is defined by rising investment in production capabilities to support complex delivery systems that ensure drug stability. For example, in the 'ALKALOID AD Skopje 2025 BUSINESS PLAN - SUMMARY' from December 2024, Alkaloid AD Skopje forecasted a 10% increase in R&D expenditure to modernize its portfolio and aid the commercialization of patented value-added medicines, including its newly launched ready-to-use liquid omeprazole.

At the same time, the creation of novel combination therapies is gaining traction as a method to address increasing antibiotic resistance in treating Helicobacter pylori infections. Manufacturers are engineering fixed-dose combinations that integrate omeprazole with advanced antibiotics to boost eradication rates and clinical effectiveness, advancing beyond basic acid suppression. This innovation enables companies to distinguish their offerings in a crowded market by providing comprehensive therapeutic regimens that streamline patient compliance. The commercial viability of these targeted treatments is demonstrated by financial performance; according to the 'RedHill Biopharma Announces First Half 2025 Financial Results' report from September 2025, net revenues for Talicia, an omeprazole-based combination therapy, rose to $3.8 million in the first half of 2025, highlighting the increasing market uptake of these specialized formulations.

Key Market Players

  • Dr. Reddy's Laboratories Inc
  • Sandoz AG
  • Perrigo Company Plc.
  • Astrazeneca Plc
  • Amneal Pharmaceuticals, Inc
  • Mylan N.V.
  • Apotex, Inc.
  • Watson Co., Ltd..
  • Santarus Inc.

Report Scope

In this report, the Global Omeprazole Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Omeprazole Market, By End-Use Application

  • Duodenal Ulcer
  • Gastric Ulcer
  • Gastroesophageal Reflux Disease
  • Erosive Esophagitis
  • Others

Omeprazole Market, By Sales Channel

  • Direct Sale
  • Indirect Sale

Omeprazole Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Omeprazole Market.

Available Customizations:

Global Omeprazole Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Omeprazole Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By End-Use Application (Duodenal Ulcer, Gastric Ulcer, Gastroesophageal Reflux Disease, Erosive Esophagitis, Others)
    • 5.2.2. By Sales Channel (Direct Sale, Indirect Sale)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Omeprazole Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By End-Use Application
    • 6.2.2. By Sales Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Omeprazole Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By End-Use Application
        • 6.3.1.2.2. By Sales Channel
    • 6.3.2. Canada Omeprazole Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By End-Use Application
        • 6.3.2.2.2. By Sales Channel
    • 6.3.3. Mexico Omeprazole Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By End-Use Application
        • 6.3.3.2.2. By Sales Channel

7. Europe Omeprazole Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By End-Use Application
    • 7.2.2. By Sales Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Omeprazole Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By End-Use Application
        • 7.3.1.2.2. By Sales Channel
    • 7.3.2. France Omeprazole Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By End-Use Application
        • 7.3.2.2.2. By Sales Channel
    • 7.3.3. United Kingdom Omeprazole Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By End-Use Application
        • 7.3.3.2.2. By Sales Channel
    • 7.3.4. Italy Omeprazole Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By End-Use Application
        • 7.3.4.2.2. By Sales Channel
    • 7.3.5. Spain Omeprazole Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By End-Use Application
        • 7.3.5.2.2. By Sales Channel

8. Asia Pacific Omeprazole Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By End-Use Application
    • 8.2.2. By Sales Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Omeprazole Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By End-Use Application
        • 8.3.1.2.2. By Sales Channel
    • 8.3.2. India Omeprazole Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By End-Use Application
        • 8.3.2.2.2. By Sales Channel
    • 8.3.3. Japan Omeprazole Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By End-Use Application
        • 8.3.3.2.2. By Sales Channel
    • 8.3.4. South Korea Omeprazole Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By End-Use Application
        • 8.3.4.2.2. By Sales Channel
    • 8.3.5. Australia Omeprazole Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By End-Use Application
        • 8.3.5.2.2. By Sales Channel

9. Middle East & Africa Omeprazole Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By End-Use Application
    • 9.2.2. By Sales Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Omeprazole Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By End-Use Application
        • 9.3.1.2.2. By Sales Channel
    • 9.3.2. UAE Omeprazole Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By End-Use Application
        • 9.3.2.2.2. By Sales Channel
    • 9.3.3. South Africa Omeprazole Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By End-Use Application
        • 9.3.3.2.2. By Sales Channel

10. South America Omeprazole Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By End-Use Application
    • 10.2.2. By Sales Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Omeprazole Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By End-Use Application
        • 10.3.1.2.2. By Sales Channel
    • 10.3.2. Colombia Omeprazole Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By End-Use Application
        • 10.3.2.2.2. By Sales Channel
    • 10.3.3. Argentina Omeprazole Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By End-Use Application
        • 10.3.3.2.2. By Sales Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Omeprazole Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Dr. Reddy's Laboratories Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Sandoz AG
  • 15.3. Perrigo Company Plc.
  • 15.4. Astrazeneca Plc
  • 15.5. Amneal Pharmaceuticals, Inc
  • 15.6. Mylan N.V.
  • 15.7. Apotex, Inc.
  • 15.8. Watson Co., Ltd..
  • 15.9. Santarus Inc.

16. Strategic Recommendations

17. About Us & Disclaimer